ES2116066T3 - ACTIVATION TEST OF THE QUINASA RECEIVER. - Google Patents

ACTIVATION TEST OF THE QUINASA RECEIVER.

Info

Publication number
ES2116066T3
ES2116066T3 ES95903133T ES95903133T ES2116066T3 ES 2116066 T3 ES2116066 T3 ES 2116066T3 ES 95903133 T ES95903133 T ES 95903133T ES 95903133 T ES95903133 T ES 95903133T ES 2116066 T3 ES2116066 T3 ES 2116066T3
Authority
ES
Spain
Prior art keywords
receptor
cells
construct
tyrosine kinase
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903133T
Other languages
Spanish (es)
Inventor
Paul J Godowski
Melanie R Mark
Michael Daniel Sadick
Wai Lee Tan Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/170,558 external-priority patent/US6001621A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2116066T3 publication Critical patent/ES2116066T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PCT No. PCT/US94/13329 Sec. 371 Date Jan. 20, 1995 Sec. 102(e) Date Jan. 20, 1995 PCT Filed Nov. 18, 1994 PCT Pub. No. WO95/14930 PCT Pub. Date Jun. 1, 1995An assay for measuring activation (i.e., autophosphorylation) of a tyrosine kinase receptor of interest is disclosed. a) A first solid phase is coated with a substantially homogeneous population of cells so that the cells adhere to the first solid phase. The cells have either an endogenous tyrosine kinase receptor or have been transformed with DNA encoding a receptor or "receptor construct" and the DNA has been expressed so that the receptor or receptor construct is presented in the cell membranes of the cells. b) A ligand is then added to the solid phase having the adhering cells, such that the tyrosine kinase receptor is exposed to the ligand. c) Following exposure to the ligand, the adherent cells are solubilized, thereby releasing cell lysate. d) A second solid phase is coated with a capture agent which binds specifically to the tyrosine kinase receptor, or, in the case of a receptor construct to the flag polypeptide. e) The cell lysate obtained in step c) is added to the wells containing the adhering capture agent so as to capture the receptor or receptor construct to the wells. f) A washing step is then carried out, so as to remove unbound cell lysate, leaving the captured receptor or receptor construct. g) The captured receptor or receptor construct is exposed to a labelled anti-phosphotyrosine antibody which identifies phosphorylated residues in the tyrosine kinase receptor. h) Binding of the anti-phosphotyrosine antibody to the captured receptor or receptor construct is measured.
ES95903133T 1993-11-23 1994-11-18 ACTIVATION TEST OF THE QUINASA RECEIVER. Expired - Lifetime ES2116066T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15756393A 1993-11-23 1993-11-23
US08/170,558 US6001621A (en) 1993-11-23 1993-12-20 Protein tyrosine kinases
US28630594A 1994-08-05 1994-08-05

Publications (1)

Publication Number Publication Date
ES2116066T3 true ES2116066T3 (en) 1998-07-01

Family

ID=27388031

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903133T Expired - Lifetime ES2116066T3 (en) 1993-11-23 1994-11-18 ACTIVATION TEST OF THE QUINASA RECEIVER.

Country Status (12)

Country Link
US (3) US6025145A (en)
EP (1) EP0730740B1 (en)
JP (1) JP3442784B2 (en)
AT (1) ATE163231T1 (en)
AU (1) AU698975B2 (en)
CA (1) CA2175892C (en)
DE (1) DE69408541T2 (en)
DK (1) DK0730740T3 (en)
ES (1) ES2116066T3 (en)
GR (1) GR3026430T3 (en)
HK (1) HK1008440A1 (en)
WO (1) WO1995014930A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG63596A1 (en) * 1993-07-29 1999-03-30 Cor Therapeutics Inc Receptor function assays
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
JP2000503204A (en) 1996-01-08 2000-03-21 ジェネンテック インコーポレーテッド WSX receptor and ligands
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
AU727606B2 (en) 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
JP4274581B2 (en) 1996-07-12 2009-06-10 ジェネンテック・インコーポレーテッド Chimera heteromultimer adhering body
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
FR2776661B1 (en) * 1998-03-26 2002-04-05 Centre Nat Rech Scient IMMUNOREACTIVE POLYPEPTIDE OF THE NGF TRKA RECEPTOR AND USES
US6253441B1 (en) * 1999-04-16 2001-07-03 General Electric Company Fabrication of articles having a coating deposited through a mask
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
AU6717200A (en) * 1999-08-06 2001-03-05 Centre National De La Recherche Scientifique-Cnrs A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate
US6406869B1 (en) * 1999-10-22 2002-06-18 Pharmacopeia, Inc. Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents
MXPA02012602A (en) 2000-06-22 2003-05-14 Genentech Inc Agonist anti-trk-c monoclonal antibodies.
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP4729254B2 (en) 2001-09-10 2011-07-20 メソ スケイル テクノロジーズ，エルエルシー Assay buffer, composition containing it, and method of use thereof
JP4694786B2 (en) * 2002-03-01 2011-06-08 ロジャー・ウィリアムズ・ホスピタル Methods and compositions related to the Shc protein for the prediction of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
ATE535254T1 (en) 2002-07-15 2011-12-15 Genentech Inc TREATING CANCER WITH THE ANTI-ERBB2 ANTIBODY RHUMAB 2C4
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
AU2003304238A1 (en) * 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
JP4584713B2 (en) * 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション Methods for treating postoperative pain by administering a nerve growth factor antagonist and compositions containing the nerve growth factor antagonist
DE60327655D1 (en) * 2002-12-23 2009-06-25 Rinat Neuroscience Corp METHOD FOR TREATING TAXOL-INDUCED SENSORIC NEUROPATHY
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ATE553128T1 (en) 2002-12-24 2012-04-15 Rinat Neuroscience Corp ANTI-NGF ANTIBODIES AND METHOD OF USE THEREOF
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EA010159B1 (en) 2003-02-19 2008-06-30 Ринат Ньюросайенс Корп. Methods for treating pain by administering a nerve growth factor antagonists and an nsaid and compositions containing the same
ES2263862T3 (en) * 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ANAPLASIC LYMPHOMA KINASE TEST, ITS REAGENTS AND COMPOSITIONS.
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
JP2006520806A (en) * 2003-03-20 2006-09-14 ライナット ニューロサイエンス コーポレイション Methods for treating taxol-induced bowel disorder
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
MXPA06011463A (en) 2004-04-07 2007-04-25 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist.
SV2006002143A (en) 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
JP4960865B2 (en) 2004-06-24 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment of conditions related to demyelination
KR20180091967A (en) 2004-07-22 2018-08-16 제넨테크, 인크. Her2 antibody composition
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1662258A1 (en) * 2004-11-25 2006-05-31 Sirenade Pharmaceuticals AG A substrate free in vitro protein kinase assay
AR050418A1 (en) 2005-01-21 2006-10-25 Genentech Inc HER ANTIBODY FIXED DOSAGE
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US7189522B2 (en) * 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
WO2006098804A2 (en) * 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
AR054260A1 (en) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME
EP1904104B1 (en) 2005-07-08 2013-09-11 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
CA2627535A1 (en) * 2005-11-11 2007-05-24 A. Raymond Frackelton, Jr. P66-shc as predictive marker in cancer treatment
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101980603A (en) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 Use of LINGO-1 and TrkB antagonists
US8097434B2 (en) 2007-10-19 2012-01-17 Becton, Dickinson And Company Methods for the detection of beta-lactamases
JP2011501190A (en) * 2007-10-24 2011-01-06 バイオマーカー ストラテジーズ リミテッド ライアビリティ カンパニー Advanced method and apparatus for cell analysis
EP2215471B1 (en) 2007-10-29 2012-02-08 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
BRPI0822049B1 (en) 2007-12-17 2021-11-16 Pfizer Limited PHARMACEUTICAL COMPOSITION COMPRISING ANTI-NGF ANTAGONIST ANTIBODY, KIT AND USE OF AN ANTINGF ANTIBODY
BRPI0907735B1 (en) 2008-02-08 2021-10-05 Astrazeneca Ab MODIFIED IGG-CLASS MONOCLONAL ANTIBODY SPECIFIC TO IFNAR1, ISOLATED NUCLEIC ACID AND PHARMACEUTICAL COMPOSITION
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
WO2010005570A2 (en) * 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
US20100022916A1 (en) 2008-07-24 2010-01-28 Javanbakhsh Esfandiari Method and Apparatus for Collecting and Preparing Biological Samples for Testing
WO2010047868A1 (en) * 2008-08-18 2010-04-29 Discoverx Corporation Receptor tyrosine kinase assays
US10188600B2 (en) 2008-09-19 2019-01-29 Pfizer Inc. Stable liquid antibody formulation
US9834807B2 (en) * 2008-10-20 2017-12-05 Becton, Dickinson And Company Compositions for the detection of intracellular bacterial targets and other intracellular micororganism targets
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
HUE033758T2 (en) 2009-10-26 2017-12-28 Hoffmann La Roche Method for the production of a glycosylated immunoglobulin
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CA2944229C (en) 2014-03-31 2023-06-13 Merck Patent Gmbh Method for detecting protein modifications using specific antibodies
ES2748688T3 (en) 2014-04-02 2020-03-17 Chembio Diagnostic Systems Inc Immunoassay using conjugate capture
US20160116466A1 (en) 2014-10-27 2016-04-28 Chembio Diagnostic Systems, Inc. Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3311889A1 (en) * 1983-03-31 1984-10-11 Byk-Mallinckrodt Chemische Produkte Gmbh, 6057 Dietzenbach METHOD FOR IRREVERSIBLE BINDING OF PROTEIN TO POLYSTYROL SURFACES WITH THE PRESERVATION OF BIOLOGICAL ACTIVITY, POLYSTYROL SURFACES OBTAINED AND THEIR USE
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
CA2128722A1 (en) * 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
CA2117913C (en) * 1992-04-10 2006-05-09 Richard J. Epstein Activation-state-specific phosphoprotein immunodetection
AU6117294A (en) * 1993-02-16 1994-09-14 Auckland Uniservices Limited Developmental tyrosine kinases and their ligands

Also Published As

Publication number Publication date
DE69408541D1 (en) 1998-03-19
ATE163231T1 (en) 1998-02-15
EP0730740A1 (en) 1996-09-11
AU698975B2 (en) 1998-11-12
WO1995014930A1 (en) 1995-06-01
US6025145A (en) 2000-02-15
AU1210895A (en) 1995-06-13
HK1008440A1 (en) 1999-05-07
CA2175892A1 (en) 1995-06-01
US5891650A (en) 1999-04-06
EP0730740B1 (en) 1998-02-11
DK0730740T3 (en) 1998-09-28
CA2175892C (en) 2000-03-07
GR3026430T3 (en) 1998-06-30
JP3442784B2 (en) 2003-09-02
JPH09505889A (en) 1997-06-10
US5914237A (en) 1999-06-22
DE69408541T2 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
ES2116066T3 (en) ACTIVATION TEST OF THE QUINASA RECEIVER.
Wilce et al. Physicochemical basis of amino acid hydrophobicity scales: evaluation of four new scales of amino acid hydrophobicity coefficients derived from RP-HPLC of peptides
IL101233A (en) Receptor-based screening and identifying methods for amylin agonists and antagonists
ATE217344T1 (en) ANTIGEN BINDING PEPTIDES (ABTIDES) FROM PEPTIDE LIBRARIES
TR200002257T2 (en) Nuclear receptor ligands and ligand binding domains.
PT842273E (en) VEGF-C RECEIVER SWITCHING
Gawler et al. CaLB: a 43 amino acid calcium-dependent membrane/phospholipid binding domain in p120 Ras GTPase-activating protein.
CA2279881A1 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
DE59914768D1 (en) Suppression of immunoassays by substances derived from the framework regions of antibodies
CA2203246A1 (en) Alk-7 (activin like kinase), a serine threonine kinase receptor
Ihara et al. [3H] BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype
CN101896816A (en) Method for detecting analytes
Suck et al. Rapid method for arrayed investigation of IgE‐reactivity profiles using natural and recombinant allergens
WO2003019136A3 (en) Methods for inhibiting angiogenesis
Chin et al. The use of tributylphosphine and 4-(aminosulfonyl)-7-fluoro-2, 1, 3-benzoxadiazole in the study of protein sulfhydryls and disulfides
Moss et al. Solubility and posttranslational regulation of GP130/F11--a neuronal GPI-linked cell adhesion molecule enriched in the neuronal membrane skeleton.
Proniewicz et al. Role of Phe‐D5 isotopically labeled analogues of bradykinin on elucidation of its adsorption mode on Ag, Au, and Cu electrodes. Surface‐enhanced Raman spectroscopy studies
DK0789844T3 (en) Use of a BMP Protein Receptor Complex for Screening for Active Substances in Bone Metabolism and Cotransfected Cells with a Type II BMP Receptor and a Type I BMP Receptor
Speth [125I] CGP 42112 binding reveals differences between rat brain and adrenal AT2 receptor binding sites
CA2294969A1 (en) Surfaces coated with streptavindin/avidin
Dybkaer Quantities and units for biological reference materials used with in vitro diagnostic measuring systems for antibodies
WO2003000732A3 (en) Fragments of the retinoic acid-related orphan receptor (ror) comprising the lig and binding domain (lbd), crystal structure of the lbd of ror-beta and their applications
AU8857991A (en) Polypeptides having human dopaminergic receptor activity, nucleic acids coding for said polypeptides and uses thereof for screening active substances on said polypeptides
Hogarth et al. Characterization of FcR Ig-binding sites and epitope mapping
Kowalczyńska et al. Semiquantitative evaluation of fibronectin adsorption on unmodified and sulfonated polystyrene, as related to cell adhesion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730740

Country of ref document: ES